Dogwood Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Sealbond Limited and Conjoint Inc. convert preferred stock into common stock, significantly increasing their beneficial ownership in Dogwood Therapeutics to 73.4% and 9.6% respectively.
NASDAQ
SCHEDULE 13D/A: Dogwood Therapeutics Converts $19.9 Million Debt to Preferred Stock with CK Life Sciences Subsidiaries
Dogwood Therapeutics, Inc. has converted approximately $19.9 million in outstanding debt and accrued interest owed to Conjoint Inc., a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., into Series A-1 Non-Voting Convertible Preferred Stock.